Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia 1Graft vs Host Disease 1

Interventions

Cyclosporine 5Cyclophosphamide 5Busulfan 4fludarabine phosphate 3fludarabine 3Mycophenolic Acid 3thymoglobulin 2Methotrexate 2Antilymphocyte Serum 2venetoclax 1trihexyltetradecylphosphonium chloride 1treosulfan 1tocilizumab 1Whole-Body Irradiation 1Thiotepa 1Tacrolimus 1Sirolimus 1Semustine 1Rituximab 1Radiotherapy 1Polymerase Chain Reaction 1Physical Therapy Modalities 1Peripheral Blood Stem Cell Transplantation 1Maraviroc 1Interferon alpha-2 1Immunoenzyme Techniques 1Drug Therapy 1Decitabine 1Cytarabine 1Cyclosporins 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Graft vs Host Disease × Semustine × Clear all
NCT04688021 2023-02-21

A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.

First Affiliated Hospital of Zhejiang University

Phase 2 Unknown
46 enrolled
Other hematologic neoplasm

Graft vs Host Disease, Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡